CD8A and neoplasm: The R848@M2pep-MPsAFP-reprogrammed M2-like TAMs not only relieved tumor immunosuppressive microenvironment, but also functioned as APCs to present AFP antigen with the help of the adjuvant R848 to drive CD8+ T cell-mediated antigen-specific antitumor immunity.